annual EBITDA:
-$154.53M+$340.60M(+68.79%)Summary
- As of today (September 16, 2025), APLS annual EBITDA is -$154.53 million, with the most recent change of +$340.60 million (+68.79%) on December 31, 2024.
- During the last 3 years, APLS annual EBITDA has risen by +$576.74 million (+78.87%).
- APLS annual EBITDA is now -3740.83% below its all-time high of -$4.02 million, reached on December 31, 2013.
Performance
APLS EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly EBITDA:
-$32.84M+$50.04M(+60.38%)Summary
- As of today (September 16, 2025), APLS quarterly EBITDA is -$32.84 million, with the most recent change of +$50.04 million (+60.38%) on June 30, 2025.
- Over the past year, APLS quarterly EBITDA has dropped by -$3.85 million (-13.26%).
- APLS quarterly EBITDA is now -125.18% below its all-time high of $130.40 million, reached on December 31, 2020.
Performance
APLS quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBITDA:
-$188.26M-$3.85M(-2.09%)Summary
- As of today (September 16, 2025), APLS TTM EBITDA is -$188.26 million, with the most recent change of -$3.85 million (-2.09%) on June 30, 2025.
- Over the past year, APLS TTM EBITDA has increased by +$123.08 million (+39.53%).
- APLS TTM EBITDA is now -6958.94% below its all-time high of -$2.67 million, reached on September 30, 2014.
Performance
APLS TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
APLS EBITDA Trends
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
---|---|---|---|
1 y1 year | +68.8% | -13.3% | +39.5% |
3 y3 years | +78.9% | +77.8% | +61.9% |
5 y5 years | +48.3% | +71.5% | +51.7% |
APLS EBITDA Highs & Lows
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
---|---|---|---|---|---|---|---|
3 y | 3-year | at high | +78.9% | -27.7% | +81.2% | -15.4% | +70.5% |
5 y | 5-year | at high | +78.9% | -125.2% | +83.1% | -15.4% | +70.5% |
alltime | all time | -3740.8% | +78.9% | -125.2% | +83.1% | -6958.9% | +70.5% |
APLS EBITDA History
Date | Annual | Quarterly | TTM |
---|---|---|---|
Jun 2025 | - | -$32.84M(-60.4%) | -$188.26M(+2.1%) |
Mar 2025 | - | -$82.88M(+222.3%) | -$184.42M(+13.0%) |
Dec 2024 | -$154.53M(-68.8%) | -$25.72M(-45.1%) | -$163.18M(-26.3%) |
Sep 2024 | - | -$46.82M(+61.5%) | -$221.49M(-28.9%) |
Jun 2024 | - | -$28.99M(-53.0%) | -$311.34M(-22.6%) |
Mar 2024 | - | -$61.65M(-26.6%) | -$402.38M(-21.9%) |
Dec 2023 | -$495.13M(-19.8%) | -$84.03M(-38.5%) | -$515.42M(-13.4%) |
Sep 2023 | - | -$136.68M(+13.9%) | -$595.01M(-2.6%) |
Jun 2023 | - | -$120.03M(-31.3%) | -$610.92M(-4.4%) |
Mar 2023 | - | -$174.68M(+6.8%) | -$639.17M(+7.8%) |
Dec 2022 | -$617.33M(-15.6%) | -$163.63M(+7.2%) | -$593.13M(+14.4%) |
Sep 2022 | - | -$152.58M(+2.9%) | -$518.52M(+5.0%) |
Jun 2022 | - | -$148.28M(+15.3%) | -$493.66M(-8.4%) |
Mar 2022 | - | -$128.64M(+44.5%) | -$539.22M(+0.8%) |
Dec 2021 | -$731.27M(+134.2%) | -$89.02M(-30.3%) | -$534.78M(+69.6%) |
Sep 2021 | - | -$127.72M(-34.1%) | -$315.36M(-0.5%) |
Jun 2021 | - | -$193.84M(+56.1%) | -$316.87M(+32.9%) |
Mar 2021 | - | -$124.20M(-195.2%) | -$238.42M(+12.0%) |
Dec 2020 | -$312.23M | $130.40M(-200.9%) | -$212.87M(-52.6%) |
Sep 2020 | - | -$129.24M(+12.0%) | -$448.99M(+15.3%) |
Date | Annual | Quarterly | TTM |
---|---|---|---|
Jun 2020 | - | -$115.39M(+17.0%) | -$389.56M(+15.4%) |
Mar 2020 | - | -$98.64M(-6.7%) | -$337.53M(+17.4%) |
Dec 2019 | -$298.83M(+139.1%) | -$105.72M(+51.5%) | -$287.42M(+31.3%) |
Sep 2019 | - | -$69.80M(+10.2%) | -$218.89M(+18.4%) |
Jun 2019 | - | -$63.35M(+30.5%) | -$184.89M(+52.1%) |
Mar 2019 | - | -$48.54M(+30.5%) | -$121.54M(+29.0%) |
Dec 2018 | -$124.99M(+146.9%) | -$37.20M(+3.9%) | -$94.23M(+65.2%) |
Sep 2018 | - | -$35.80M(+68.7%) | -$57.03M(+26.9%) |
Mar 2018 | - | -$21.23M(+83.2%) | -$44.95M(+14.4%) |
Dec 2017 | -$50.63M(+86.7%) | - | - |
Sep 2017 | - | -$11.59M(-4.5%) | -$39.30M(+12.5%) |
Jun 2017 | - | -$12.13M(+34.0%) | -$34.94M(+53.2%) |
Mar 2017 | - | -$9.05M(+38.8%) | -$22.81M(+65.8%) |
Dec 2016 | -$27.12M(+35.0%) | -$6.52M(-9.9%) | -$13.76M(-3.1%) |
Sep 2016 | - | -$7.23M(+3.9%) | -$14.20M(+17.1%) |
Dec 2015 | -$20.09M(+78.0%) | -$6.96M(+35.0%) | -$12.12M(+50.2%) |
Sep 2015 | - | -$5.16M(+77.0%) | -$8.07M(+44.6%) |
Dec 2014 | -$11.29M(+180.6%) | -$2.91M(+9.3%) | -$5.58M(+109.3%) |
Sep 2014 | - | -$2.67M | -$2.67M |
Dec 2013 | -$4.02M | - | - |
FAQ
- What is Apellis Pharmaceuticals, Inc. annual EBITDA?
- What is the all time high annual EBITDA for Apellis Pharmaceuticals, Inc.?
- What is Apellis Pharmaceuticals, Inc. annual EBITDA year-on-year change?
- What is Apellis Pharmaceuticals, Inc. quarterly EBITDA?
- What is the all time high quarterly EBITDA for Apellis Pharmaceuticals, Inc.?
- What is Apellis Pharmaceuticals, Inc. quarterly EBITDA year-on-year change?
- What is Apellis Pharmaceuticals, Inc. TTM EBITDA?
- What is the all time high TTM EBITDA for Apellis Pharmaceuticals, Inc.?
- What is Apellis Pharmaceuticals, Inc. TTM EBITDA year-on-year change?
What is Apellis Pharmaceuticals, Inc. annual EBITDA?
The current annual EBITDA of APLS is -$154.53M
What is the all time high annual EBITDA for Apellis Pharmaceuticals, Inc.?
Apellis Pharmaceuticals, Inc. all-time high annual EBITDA is -$4.02M
What is Apellis Pharmaceuticals, Inc. annual EBITDA year-on-year change?
Over the past year, APLS annual EBITDA has changed by +$340.60M (+68.79%)
What is Apellis Pharmaceuticals, Inc. quarterly EBITDA?
The current quarterly EBITDA of APLS is -$32.84M
What is the all time high quarterly EBITDA for Apellis Pharmaceuticals, Inc.?
Apellis Pharmaceuticals, Inc. all-time high quarterly EBITDA is $130.40M
What is Apellis Pharmaceuticals, Inc. quarterly EBITDA year-on-year change?
Over the past year, APLS quarterly EBITDA has changed by -$3.85M (-13.26%)
What is Apellis Pharmaceuticals, Inc. TTM EBITDA?
The current TTM EBITDA of APLS is -$188.26M
What is the all time high TTM EBITDA for Apellis Pharmaceuticals, Inc.?
Apellis Pharmaceuticals, Inc. all-time high TTM EBITDA is -$2.67M
What is Apellis Pharmaceuticals, Inc. TTM EBITDA year-on-year change?
Over the past year, APLS TTM EBITDA has changed by +$123.08M (+39.53%)